February, 28 2019 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”) is proud to announce it is a silver sponsor of the Arnold Sports Festival from February 28 – March 3, 2019 in Columbus, Ohio.
With the World Anti-Doping Agency (WADA) removing hemp-derived cannabidiol (CBD) from its list of Prohibited Substances, the Company has been steadfast in targeting athletes for the use of CBD for general healing and treatment. Overall, the Arnold Sports Festival provides a tremendous opportunity for an estimated 200,000 sports and fitness fans to watch more than 22,000 athletes compete in 80 sports and events, including 16 Olympic events, at venues such as the Greater Columbus Convention Center, the Ohio Expo Center, and various other Central Ohio venues.
Attendees can visit Iso-Sport at this year’s festival at booth #611. While visiting the booth, attendees will be able to meet Iso-Sport Ambassador and two-time Mr. Olympia, Franco Columbu. Isodiol’s Vice President and Director, Marvin Washington, also will be a guest speaker at the festival to help educate attendees about the benefits of using CBD with their workouts.
“As an advocate for all-natural, non-habit-forming supplements and pain relief, I will be educating attendees on using CBD as a neuroprotectant and anti-inflammatory agent to help improve their workouts and recovery,” said Washington. “We were able to make significant headway with all types of athletes at the Arnold last year, and we anticipate an even greater opportunity this year, as consumers around the globe continue to embrace CBD.”
To learn more about Iso-Sport products, visit: Iso-Sport.com
About Isodiol International Inc.
Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based consumer products and solutions.
Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.
Join Us On Facebook: https://www.facebook.com/IsodiolInternationalInc/
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, proposed arrangement with creditors, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.